Journal articles: 'Aventis'

1

MULLIN, RICK. "SEEKING AVENTIS." Chemical & Engineering News 82, no. 13 (March 29, 2004): 8. http://dx.doi.org/10.1021/cen-v082n013.p008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bouchie, Aaron J. "Aventis to shed ag." Nature Biotechnology 19, no. 1 (January 2001): 5. http://dx.doi.org/10.1038/83528.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

REISCH, MARC. "AVENTIS PAINTS ROSY FUTURE." Chemical & Engineering News Archive 80, no. 25 (June 24, 2002): 16. http://dx.doi.org/10.1021/cen-v080n025.p016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bouselli, Anthony. "sanofi-aventis U.S. Award." Microbe Magazine 1, no. 9 (September 1, 2006): 432–33. http://dx.doi.org/10.1128/microbe.1.432.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Triamcinolone Acetonide Hydrofluoroalkane Inhalation ??? Aventis." Drugs in R & D 3, no. 2 (2002): 141–42. http://dx.doi.org/10.2165/00126839-200203020-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

J.-M.M. "Sanofi-Aventis Ex-Sanofi-Synthelabo." Revue Française des Laboratoires 2004, no. 366 (October 2004): 8. http://dx.doi.org/10.1016/s0338-9898(04)80124-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

MULLIN, RICK. "AVENTIS, AMGEN INK PRICEY DEALS." Chemical & Engineering News 81, no. 37 (September 15, 2003): 6. http://dx.doi.org/10.1021/cen-v081n037.p006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

THAYER, ANN. "Aventis Exiting Its CropScience Business." Chemical & Engineering News 78, no. 47 (November 20, 2000): 11–12. http://dx.doi.org/10.1021/cen-v078n047.p011a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

THAYER, ANN. "AVENTIS, ANDRX IN ANTITRUST SUIT." Chemical & Engineering News 79, no. 21 (May 21, 2001): 10. http://dx.doi.org/10.1021/cen-v079n021.p010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dorey, Emma. "Genta strikes bumper deal with Aventis." Nature Biotechnology 20, no. 6 (June 2002): 533–34. http://dx.doi.org/10.1038/nbt0602-533b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Mitchell, Peter. "Sanofi takeover jeopardizes Aventis biotech deals." Nature Biotechnology 22, no. 6 (June 2004): 639–40. http://dx.doi.org/10.1038/nbt0604-639.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Fletcher, Liz. "Millennium and Aventis in unique pact." Nature Biotechnology 18, no. 8 (August 2000): 817. http://dx.doi.org/10.1038/78410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kühni, Christian, and Björn Christmann. "Corporate real estate management at Aventis." Journal of Corporate Real Estate 6, no. 3 (July 2004): 265–77. http://dx.doi.org/10.1108/14630010410812388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

SHORT, PATRICIA. "SANOFI UPS OFFER TO WIN AVENTIS." Chemical & Engineering News 82, no. 18 (May 3, 2004): 8. http://dx.doi.org/10.1021/cen-v082n018.p008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

HILEMAN, BETTE. "Aventis Suspends Bt Corn Seed Sales." Chemical & Engineering News 78, no. 40 (October 2, 2000): 13. http://dx.doi.org/10.1021/cen-v078n040.p013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

J.-M. M. "TVP: nouvel anti-Xachez Sanofi-Aventis." Revue Francophone des Laboratoires 2007, no. 389 (February 2007): 10. http://dx.doi.org/10.1016/s1773-035x(07)80042-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

THAYER, ANN. "Farmers Sue Aventis Over StarLink Corn." Chemical & Engineering News 78, no. 50 (December 11, 2000): 10–11. http://dx.doi.org/10.1021/cen-v078n050.p010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

THAYER, ANN. "Aventis CropScience: Whole Or In Parts?" Chemical & Engineering News Archive 79, no. 13 (March 26, 2001): 21. http://dx.doi.org/10.1021/cen-v079n013.p021a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Moran, Nuala. "Sanofi-aventis snaps up microRNA maker." Nature Biotechnology 28, no. 9 (September 2010): 880. http://dx.doi.org/10.1038/nbt0910-880.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hicks, Brian. "Aventis - a new leader in life sciences." Pesticide Outlook 11, no. 3 (2000): 116–18. http://dx.doi.org/10.1039/b006361o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kalaria, Raj. "WHO AND AVENTIS TO TACKLE SLEEPING SICKNESS." Neuroreport 12, no. 10 (July 2001): A65—A66. http://dx.doi.org/10.1097/00001756-200107200-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

THAYER, ANN. "BAYER IN LEAD FOR AVENTIS AG UNIT." Chemical & Engineering News 79, no. 29 (July 16, 2001): 6. http://dx.doi.org/10.1021/cen-v079n029.p006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

LAYMAN, PATRICIA. "Aventis merger marches forward at double time." Chemical & Engineering News 77, no. 21 (May 24, 1999): 8. http://dx.doi.org/10.1021/cen-v077n021.p008a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ratner, Mark. "Genzyme resumes shipping as Sanofi-aventis hovers." Nature Biotechnology 28, no. 10 (October 2010): 994. http://dx.doi.org/10.1038/nbt1010-994c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hauthal, Hermann G. "Grünes Licht für das Bioindustrie-Unternehmen Aventis." Nachrichten aus Chemie, Technik und Laboratorium 47, no. 10 (October 1999): 1242–43. http://dx.doi.org/10.1002/nadc.19990471017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Schmidt, Hartmut. "Unfriendly Takeover." kma - Klinik Management aktuell 9, no. 02 (February 2004): 10–11. http://dx.doi.org/10.1055/s-0036-1572619.

Full text

Abstract:

Eins plus ein muss größer sein als zwei, nur dann sind Fusionen sinnvoll.Im Falle von Aventis und Sanofi-Synthelabo könnte diese Rechnung aufgehen. Denn Versäumnisse in der Unternehmensführung machen Aventis zur leichten Beute. Die Gewinner und Verlierer stehen auch schon fest.

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Aventis has launched insulin glargine ['Lantus'] in France." Inpharma Weekly &NA;, no. 1403 (September 2003): 18. http://dx.doi.org/10.2165/00128413-200314030-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Henn, David, and Samuel Amell. "La narrativa de Juan Marse, contador de aventis." Modern Language Review 82, no. 3 (July 1987): 767. http://dx.doi.org/10.2307/3730492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bellver, C. G., and Samuel Amell. "La narrativa de Juan Marsé: Contador de aventis." World Literature Today 60, no. 1 (1986): 83. http://dx.doi.org/10.2307/40141172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Moran, Nuala. "Sanofi Aventis grooms its ranks for biotech partnering." Nature Biotechnology 27, no. 7 (July 2009): 581–82. http://dx.doi.org/10.1038/nbt0709-581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Leaver, Adam, and Matthieu Montalban. "Sanofi-Aventis and the Complexity of Capitalist Organization." Competition & Change 14, no. 1 (March 2010): 1–22. http://dx.doi.org/10.1179/102452910x12587274067999.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Manus, Jean-Marie. "Aventis, nouveau géant franco-européen de l'industrie pharmaceutique." Revue Française des Laboratoires 2000, no. 322 (April 2000): 8–9. http://dx.doi.org/10.1016/s0338-9898(00)80448-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Frantz, Simon. "Aventis-Sanofi: a good R&D merger?" Nature Reviews Drug Discovery 3, no. 3 (March 2004): 193–94. http://dx.doi.org/10.1038/nrd1358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

. "1189 Sanofi-Aventis Boekt Winstgroei Van 4,9 Procent." Zorg en Financiering 8, no. 8 (August 2009): 100. http://dx.doi.org/10.1007/bf03098858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Bengs, Holger. "Die erste SEC-Technology-Tour bei Sanofi-Aventis." Nachrichten aus der Chemie 55, no. 4 (April 2007): 461. http://dx.doi.org/10.1002/nadc.200749184.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Netting, Jessa. "Aventis gets short shrift over release of modified corn." Nature 408, no. 6811 (November 2000): 395. http://dx.doi.org/10.1038/35044248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

J.-M. M. "Sanofi-Aventis + OMS: alliance pour les maladies tropicales négligées." Revue Francophone des Laboratoires 2006, no. 387 (December 2006): 10. http://dx.doi.org/10.1016/s1773-035x(06)80472-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Moran, Nuala. "Erratum: Sanofi Aventis grooms its ranks for biotech partnering." Nature Biotechnology 27, no. 10 (October 2009): 957. http://dx.doi.org/10.1038/nbt1009-957a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sandhu, Suneet, Devinder Gill, Paul David Turner, William E. P. Renwick, Maya Latimer, Naomi Mackinlay, Leanne Berkahn, et al. "Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial." Blood 126, no. 23 (December 3, 2015): 5295. http://dx.doi.org/10.1182/blood.v126.23.5295.5295.

Full text

Abstract:

Abstract Background The diagnosis and treatment of CLL may have a great impact on the quality of life (QoL) due to a variety of reasons including disease-related symptoms, infection, effects of therapy and the emotional, socio-economic, and functional effects of living with an 'incurable' illness. The main aim of any treatment is to maximize QoL by inducing remission with minimal short- and long-term toxicity. Balancing disease and symptom control with QoL in elderly patients receiving CLL therapy regimens can be challenging. There is little published QoL data in elderly CLL patients receiving the FCR (fludarabine, cyclophosphamide, rituximab) immunochemotherapy regimen. Our prior study showed no significant difference in health related QoL for first-line therapy of CLL with monotherapy between chlorambucil, fludarabine and cladribine (Mulligan, SP et al. Leuk Lymphoma, 2014). Aim We report the QoL assessments of CLL patients enrolled in the ALLG clinical trial CLL5, a randomised, 3-arm, dose de-escalation study of the FCR regimen. Methods The treatment schedule has been described with fit elderly patients randomly assigned to one of three treatment regimens: FR5, FCR3, and FCR5 (Mulligan SP et al. iwCLL Abstract, 2015). Treatment was repeated every 28 days for a planned total of 6 cycles. Importantly, an early stopping rule mandating cessation of therapy was included for any patient having grade 3 or 4 toxicity lasting >2 weeks. QoL assessments using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were measured at 8 time points: before commencement of therapy, at the end of the 3rd and 6th cycles of treatment, at the final staging and thereafter every 3 months for 12 months. Results Of the 116 evaluable in the study, 2 patients had no QoL data, 6 patients had only baseline QoL data, and 4 patients had no baseline QoL data, therefore the number of patients included in the QoL analysis was 104. There appeared to be a trend towards improved global health (figure 1), physical functioning (figure 2) and role functioning with full dose (FCR5) towards the end of the follow-up period compared to commencement of therapy. Comparison of cognitive functioning (figure 3) between the three arms showed a statistically significant improvement with FCR5. However, on multivariate analysis there was no statistical significant difference. Conclusions Despite a trend favouring full-dose FCR, there were no definitively significant differences in the QoL domains following treatment with FCR-based immunochemotherapy between the three different groups. QoL continues to be a neglected issue, particularly for the typical elderly CLL patient. This study highlights the need for objective QoL assessment as part of all CLL trials, especially those targeted in the typical elderly patient. Figure 1. Mean change from baseline global health status scores with 95% confidence intervals Figure 1. Mean change from baseline global health status scores with 95% confidence intervals Figure 2. Mean change from baseline physical functioning scores with 95% confidence intervals Figure 2. Mean change from baseline physical functioning scores with 95% confidence intervals Figure 3. Mean change from baseline cognitive functioning scores with 95% confidence intervals Figure 3. Mean change from baseline cognitive functioning scores with 95% confidence intervals Disclosures Gill: Roche: Research Funding; Sanofi Aventis: Research Funding; AbbVie: Honoraria; Roche: Honoraria. Turner:Roche: Research Funding; Sanofi Aventis: Research Funding. Renwick:Sanofi Aventis: Research Funding; Roche: Research Funding. Latimer:Sanofi Aventis: Research Funding; Roche: Research Funding. Mackinlay:Sanofi Aventis: Research Funding; Roche: Research Funding. Berkahn:Sanofi Aventis: Research Funding; Roche: Research Funding. Simpson:Janssen-Cilag: Honoraria; Celgene: Honoraria; Onyx Pharmaceuticals: Research Funding; Roche: Honoraria. Forsyth:Sanofi Aventis: Research Funding; Roche: Research Funding. Cull:Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Travel. Harrup:Roche: Research Funding; Sanofi Aventis: Research Funding. Kuss:Sanofi Aventis: Research Funding; Roche: Research Funding. Mulligan:Sanofi Aventis: Research Funding; Janssen: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau.

APA, Harvard, Vancouver, ISO, and other styles

40

Amin, Alpesh, Jay Lin, Guiping Yang, and Steve Stemkowski. "Clinical and Economic Outcomes Following Full or Partial ACCP Recommended Prophylaxis in Cancer Patients at Risk of Venous Thromboembolism." Blood 112, no. 11 (November 16, 2008): 169. http://dx.doi.org/10.1182/blood.v112.11.169.169.

Full text

Abstract:

Abstract Background: As hospitalized cancer patients are at high risk of venous thromboembolism (VTE), evidence-based guidelines recommend VTE prophylaxis in this population. However, although VTE prophylaxis is frequently provided to at-risk medical and surgical cancer patients, it often fails to meet the criteria for best practice recommendations. As few data are available on the impact of inappropriate prophylaxis on clinical outcomes, we compare the safety and efficacy of fully appropriate or partially appropriate VTE prophylaxis in cancer patients using data from a large hospital administrative database. Methods: Discharges from the Premier Perspective database (Jan 02–Dec 06) with a principal diagnosis of cancer, age ≥40 years, length of stay ≥6 days, and receiving some form of VTE prophylaxis, were included in the analysis. Discharges were excluded if they were transferred from another acute care facility or had any contraindications to VTE prophylaxis. Discharges were divided into two groups: full prophylaxis, receiving ACCP-recommended prophylaxis for a sufficient duration (length of stay minus 2 days; minimum 3 days); partial prophylaxis, receiving some form of prophylaxis that was not recommended by the ACCP guidelines, or receiving a guideline-recommended prophylaxis type, but for an insufficient duration. VTE, readmission, bleeding, mortality rates, and total hospital costs were collected and compared between groups using multivariate regression modelling. Results: Among the 83,794 eligible discharges, the full prophylaxis group (n = 13,387, 16%) had a lower in-hospital VTE rate than the partial prophylaxis (n = 70,407, 84%) group (0.8% vs. 2.9%; odds ratio [OR] 3.09, 95% confidence intervals [CI] 2.51–3.80). Similarly, in-hospital mortality rates were lower in the full prophylaxis group (2.6% vs. 4.2%; OR 1.48, 95% CI 1.29–1.69). No major bleeding events were observed in either group, potentially due to the miscoding of these events. The mean total hospital cost was higher for patients receiving partial prophylaxis ($17,128) than full prophylaxis ($15,284). Conclusion: US cancer patients receiving partial prophylaxis have a higher risk of VTE and mortality than patients receiving full guideline-recommended prophylaxis, leading to a higher total hospital cost. It is important that individual hospitals improve the use of full prophylaxis to reduce both the clinical and economic burden posed by VTE. Disclosures: Amin: sanofi-aventis: Consultancy, Financial and editorial support for this publication was provided by sanofi-aventis US, Inc., Honoraria. Lin:sanofi-aventis: Employment. Yang:sanofi-aventis: employee of Premier Inc which has received funding to perform this research from sanofi-aventis. Stemkowski:sanofi-aventis: employee of Premier Inc which has received funding to perform this research from sanofi-aventis.

APA, Harvard, Vancouver, ISO, and other styles

41

Rezende, Pedro Milanez de, and Eudes de Arruda Carvalho. "Avaliação de cultivares de soja [Glycine max (L.) Merrill] para o sul de Minas Gerais." Ciência e Agrotecnologia 31, no. 6 (December 2007): 1616–23. http://dx.doi.org/10.1590/s1413-70542007000600003.

Full text

Abstract:

Visando gerar informações que auxiliem técnicos e produtores na escolha da cultivar a ser utilizada em Lavras e região em plantio de verão, foi desenvolvido o presente trabalho no campo experimental da Universidade Federal de Lavras, no ano agrícola 2002/03, utilizando-se delineamento de blocos casualizados com três repetições e 45 tratamentos, constituídos pelas cultivares: Doko RC, Pioneira, Virtuosa, Conquista, FT-104, Monarca, Monsoy 108, Monsoy 109, FT-Abyara, Performa, Liderança, Monsoy 8400, Confiança, Splendor, UFV-16, Garantia, Renascença, IAC-19, FT-2000, IAC-21, CAC-1, Monsoy 8411, Suprema, Segurança, Aventis 7002, Paiaguás, Carrera, Santa Rosa, BRS - Celeste, DM 339, BRS Carla, BRS Milena, Vencedora, BR-9 Savana, Aventis 2056-7, STTE 02, Aventis 1043, Monsoy 8866, Monsoy 8329, Monsoy 9010, Embrapa 48, Emgopa 313, Emgopa 314, Tucano e BRS 136. As cultivares apresentaram produtividades satisfatórias, com destaque para Vencedora (4.395 kg.ha-1), Paiaguás (3.897 kg.ha-1), Aventis 2056-7 (3.780 kg.ha-1), Monarca (3.646 kg.ha-1) e FT 2000 (3.498 kg.ha-1). Altura da planta e inserção do primeiro legume variaram de 0.68 a 1,53m e de 0.08 a 0.29 m, respectivamente. O índice de acamamento foi satisfatório para todas cultivares testadas. A qualidade da semente foi avaliada através do critério de notas variando de 1 a 2.3 numa escala de 1 a 5.

APA, Harvard, Vancouver, ISO, and other styles

42

Walenga, Jeanine M., Walter Jeske, Debra Hoppensteadt, Josephine Cunanan, Vicki Escalante, Hussein Khan, Joseph Bailey, Jawed Fareed, and Mamdouh Bakhos. "Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin." Blood 120, no. 21 (November 16, 2012): 2264. http://dx.doi.org/10.1182/blood.v120.21.2264.2264.

Full text

Abstract:

Abstract Abstract 2264 Background: Low molecular weight heparins (LMWHs) are complex biologic drugs whose heterogeneity in saccharide chain length and in the composition (sulfate, acetyl), content, and location of functional groups can impact their multiple biologic activities. Enoxaparin (Lovenox®) is validated for multiple indications and is the most widely used LMWH in the US. Several generic versions of enoxaparin are currently available in the US. We undertook this study to compare the activity profile of branded and a generic enoxaparin. Methods: Five batches each of branded (B; Sanofi-aventis; Bridgewater, NJ) and generic (G; Sandoz US; Princeton, NJ) enoxaparin were studied. Drugs were purchased through hospital pharmacies as pre-filled syringes containing 40 mg drug. The molecular weight profile of each batch of LMWH was determined using HPLC. To analyze in vitro activities, LMWHs were supplemented to normal human plasma and assessed using amidolytic anti-FXa and anti-FIIa, fibrinokinetic, and thrombin generation assays. Human whole blood was supplemented with LMWHs and the dynamic blood coagulation process was analyzed by thrombelastography (TEG). Whole blood flow cytometry was used to assess the ability of the LMWHs to inhibit tissue factor (TF)-induced platelet activation and lipopolysaccharide (LPS)-induced neutrophil activation. To assess the in vivo effect of the LMWHs, primates treated subcutaneously with a dose of 1 mg/kg LMWH had blood samples drawn pre-treatment and at 4, 6, 12 and 24 hours. Ex vivo pharmacodynamic activities of TFPI release, TAFI inhibition, and thrombin generation inhibition were evaluated. Results: Molecular weight parameters and IC50 values for FXa and FIIa inhibition by branded and generic enoxaparin were comparable. In the in vitro thrombin generation and fibrinokinetic assays, branded enoxaparin exhibited a more potent anticoagulant effect demonstrating slower clot formation with a weaker final clot structure (p=0.01) than generic enoxaparin. Although both the branded and generic enoxaparin produced a concentration-dependent anticoagulant effect in the TEG, there was greater degree of variability for the generic product between blood donors and between batches resulting in a less predictable linear response as drug concentration increased. When the increase in TEG R-time was plotted vs. concentration, branded enoxaparin showed a stronger anticoagulant effect (p=0.05). A concentration-dependent reduction in TF-induced platelet P-selectin expression was observed with branded and generic enoxaparin producing a similar effect. Incubation of whole blood with LPS resulted in a dramatic increase in neutrophil CD11b expression (MFI: 13.1±2.8 vs. 249.0±42.1) which was reduced by increasing concentrations of LMWH. This effect appeared to be stronger for generic than branded enoxaparin (MFI: 165.2±31.9 vs. 208.9±25.9). In primates treated with branded and generic enoxaparin, anti-FXa activity assessed by AUC 0–24hrs was similar. Anti-FIIa activity, however, was significantly higher in primates treated with generic enoxaparin (135±28 vs. 91±20 (μg*hr)/ml; p=0.023). AUC for thrombin generation inhibition was (B) 932±59 vs. (G) 775±119 %inhibition*hr; p=0.029. AUC for TFPI release was (B) 1101±98 vs. (G) 822±13 (ng/*hr)/ml; p=0.006. AUC for inhibition of TAFI activation was (B) 780±73 vs. 906±69 % inhibition*hr; p=0.023. Conclusions: This investigation demonstrated a wider variation in anticoagulant response to generic enoxaparin in comparison to branded enoxaparin. This variation was due to the response of the individual subject as well as to the batch of the product. In addition, both in vitro and in vivo/ex vivo activity differences were observed between branded and generic enoxaparin in several parameters relevant to the antithrombotic effect of LMWH. These findings suggest that simple analytical characterization can establish good quality control in manufacturing but may not assure similarity in biological performance between branded and generic enoxaparin. Thus beside the routinely required characterization, inclusion of additional tests for biologic activities and pharmacodynamic profiling of generic products in animal models may provide useful information on the bioequivalence of the generic versions of enoxaparin. Disclosures: Walenga: Sanofi-Aventis, Paris, France: Research Funding. Jeske:Sanofi-Aventis, Paris, France: Research Funding. Hoppensteadt:Sanofi-Aventis, Paris, France: Research Funding. Cunanan:Sanofi-Aventis, Paris, France: Research Funding. Escalante:Sanofi-Aventis, Paris, France: Research Funding. Khan:Sanofi-Aventis, Paris, France: Research Funding. Bailey:Sanofi-Aventis, Paris, France: Research Funding. Fareed:Sanofi-Aventis, Paris, France: Research Funding. Bakhos:Sanofi-Aventis, Paris, France: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

43

Amin, Alpesh N., Jay Lin, and Daniel Wiederkehr. "Prevention of Deep Vein Thrombosis In Patients In the United States with Infectious Diseases." Blood 116, no. 21 (November 19, 2010): 4389. http://dx.doi.org/10.1182/blood.v116.21.4389.4389.

Full text

Abstract:

Abstract Abstract 4389 Background: Hospitalized patients with infectious diseases are at risk of venous thromboembolism (VTE), encompassing both deep-vein thrombosis (DVT) and pulmonary embolism (PE). Our analysis evaluated real-world thromboprophylaxis use and DVT/PE rates in patients with infectious diseases in hospital, and for 30 days post-discharge. Methods: Data were extracted from the US Premier Perspective(tm)-i3 Pharma Informatics linked database for patients with infectious disease (International Classification of Diseases Ninth Revision codes for infectious and parasitic diseases, skin infections, chronic infection, and postoperative infection) who had been admitted January 2005–November 2007. Included patients had at least 6 months’ continuous plan enrollment and were aged ≥ 18 years. Patients with a diagnosis of atrial fibrillation were excluded, as were patients with a hospital stay of 0 days or > 30 days. Results: Of the 5,488 at-risk patients analyzed, 31% received inpatient pharmacological or mechanical DVT prophylaxis, and 3.2% received outpatient pharmacological DVT prophylaxis. Mean ± standard deviation duration of prophylaxis was 1.1 ± 2.4 days for inpatients and 0.8 ± 4.6 days post-discharge, with a total duration of 1.9 ± 5.4 days. DVT/PE occurred in 3.61% of patients during hospitalization, and 0.98% of patients were rehospitalized or treated in the outpatient setting for DVT/PE. Conclusions: Our analysis highlights the considerable rate of DVT/PE and the underuse of DVT prophylaxis in hospitals. Furthermore, DVT/PE risk persisted post-discharge, yet few patients received outpatient prophylaxis. Improved prevention of DVT is required across the continuum of care to reduce preventable mortality and morbidity in patients with infectious diseases. Acknowledgment: this study was funded by sanofi-aventis U.S., Inc. The authors received editorial/writing support in the preparation of this abstract provided by Hester van Lier, PhD of Excerpta Medica, funded by sanofi-aventis U.S., Inc. Disclosures: Amin: sanofi-aventis US Inc.: Honoraria, Speakers Bureau. Lin:sanofi-aventis US Inc.: Employment, Research Funding. Wiederkehr:sanofi-aventis US Inc.: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

44

Oza, A. M., V. Castonguay, D. Tsoref, I. Diaz–Padilla, K. Karakasis, H. Mackay, S. Welch, et al. "Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective." Current Oncology 18, no. 6 (December 1, 2011): 303. http://dx.doi.org/10.3390/curroncol18060003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Aventis' oral DMARD 'Arava' [leflunomide] has been launched in Japan." Inpharma Weekly &NA;, no. 1405 (September 2003): 21. http://dx.doi.org/10.2165/00128413-200314050-00055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

JARVIS, LISA. "PHARMACEUTICALS Sanofi-Aventis sets its sights on biotech firm Genzyme." Chemical & Engineering News 88, no. 32 (August 9, 2010): 7. http://dx.doi.org/10.1021/cen-v088n032.p007a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Aventis." Acta Endoscopica 30, S1 (September 2000): 295–96. http://dx.doi.org/10.1007/bf03021877.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Aventis Pharmaceuticals." Annals of Oncology 12, no. 5 (May 2001): 732–34. http://dx.doi.org/10.1093/oxfordjournals.annonc.a000269.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Aventis Pharmaceuticals." Annals of Oncology 12, no. 8 (August 2001): 1182. http://dx.doi.org/10.1023/a:1011607620350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"sanofi aventis." Annals of Oncology 19 (June 2008): iv266. http://dx.doi.org/10.1093/annonc/mdn274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Aventis'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles